Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

302
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.0K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Latent twins: a framework for scene recognition and fast radiative transfer inversion in FORUM all-sky observations.

Scientific reports·2026
Same author

North American Culex pipiens mosquitoes are competent for Usutu virus transmission.

Npj viruses·2026
Same author

Accelerated reconstruction of 5D free-running MRI with variable projection-augmented Lagrangian (VPAL).

Magnetic resonance imaging·2026
Same author

From Bird Viremia to Bird Surveillance: Identifiability in a Multiscale Vector-Borne Model of Usutu Virus Infection.

bioRxiv : the preprint server for biology·2025
Same author

Investigation of a Two-Patch Within-Host Model of Hepatitis B Viral Infection.

Bulletin of mathematical biology·2025
Same author

Structural and practical identifiability of within-host models of virus dynamics - a review.

Current opinion in systems biology·2025
Same journal

Correction: Bulatov et al. Camelpox Virus in Western Kazakhstan: Assessment of the Role of Local Fauna as Reservoirs of Infection. <i>Viruses</i> 2024, <i>16</i>, 1626.

Viruses·2026
Same journal

Correction: Franco et al. Whole Blood Volume-Based Absolute Quantification of HTLV-1 Proviral Load: A Comparative Method Evaluation Study. <i>Viruses</i> 2026, <i>18</i>, 580.

Viruses·2026
Same journal

Correction: Medkour et al. Adenovirus Infections in African Humans and Wild Non-Human Primates: Great Diversity and Cross-Species Transmission. <i>Viruses</i> 2020, <i>12</i>, 657.

Viruses·2026
Same journal

Burden of Malaria and Dengue Across Global, Asian, and Chinese Populations Based on GBD 2021 Data: A Quantitative Assessment of Importation Risks to China.

Viruses·2026
Same journal

First Report of <i>Orthonairovirus songlingense</i> in <i>Haemaphysalis concinna</i> Ticks from Russia.

Viruses·2026
Same journal

Epidemiological and Virological Characteristics of H9N2 Avian Influenza Virus in Jiangsu Province, China, 2024.

Viruses·2026
See all related articles

Related Experiment Video

Updated: Mar 2, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Understanding the Complex Patterns Observed during Hepatitis B Virus Therapy.

Andrea Carracedo Rodriguez1, Matthias Chung2, Stanca M Ciupe3

  • 1Department of Mathematics, Virginia Tech, 460 McBryde Hall, Blacksburg, VA 24060, USA. crandrea@vt.edu.

Viruses
|May 24, 2017
PubMed
Summary
This summary is machine-generated.

Understanding hepatitis B virus (HBV) dynamics is key. Our model reveals that initial liver infection levels and immune response strength significantly impact antiviral therapy outcomes and virus resolution.

Keywords:
Monte Carlodrug therapyhepatitis B virus (HBV)virus kinetics

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.2K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Related Experiment Videos

Last Updated: Mar 2, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.2K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Area of Science:

  • Virology
  • Mathematical Modeling
  • Immunology

Background:

  • Hepatitis B virus (HBV) exhibits complex decay and rebound kinetics in patients undergoing antiviral therapy.
  • Observed patterns include bi-phasic, tri-phasic, stepwise decay, and rebound phenomena.

Purpose of the Study:

  • To elucidate the mechanistic interactions governing HBV dynamics during antiviral therapy.
  • To identify key virological, pharmacological, and immunological factors differentiating HBV decay profiles.

Main Methods:

  • Utilized a deterministic mathematical model of HBV kinetics.
  • Performed analytical investigation to separate parameters for virus decay and rebound.
  • Employed Monte Carlo sampling to explore the parameter space.

Main Results:

  • Initial level of liver infection at therapy onset is the primary differentiator of decay patterns.
  • Drug efficacy, cell division ratios (uninfected vs. infected), and cytotoxic immune response strength influence outcomes.
  • These factors are crucial for assessing liver damage and predicting therapy duration for virus resolution.

Conclusions:

  • The study successfully models complex HBV kinetics, identifying critical factors influencing treatment response.
  • Initial viral load and immune response strength are key predictors of therapy success and duration.
  • This mechanistic understanding aids in optimizing antiviral strategies for hepatitis B virus.